Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

CTAD 2023

24–27 October 2023 | Boston, MA

CTAD 2023

24–27 October 2023 | Boston, MA
The future of Alzheimer’s disease diagnosis: blood biomarkers and amyloid-PET 2:50
The future of Alzheimer’s disease diagnosis: blood biomarkers and amyloid-PET
Robin Wolz • 25 Oct 2023
Reducing caregiver burden with a digital care coordination platform 2:16
Reducing caregiver burden with a digital care coordination platform
Ram Kinker Mishra • 8 Nov 2023
Speech biomarkers for cognitive decline detection 4:23
Speech biomarkers for cognitive decline detection
Ram Kinker Mishra • 8 Nov 2023
Plasma biomarkers for population-based Alzheimer’s disease screening 2:25
Plasma biomarkers for population-based Alzheimer’s disease screening
Pamela Lukasewicz Ferreira • 30 Oct 2023
Amyloid-PET positivity cut-offs: insights from INTERCEPT-AD 3:16
Amyloid-PET positivity cut-offs: insights from INTERCEPT-AD
Eric Siemers • 8 Nov 2023
Measuring treatment effect in Alzheimer’s disease clinical trials: the ‘time saved’ approach 7:43
Measuring treatment effect in Alzheimer’s disease clinical trials: the ‘time saved’ approach
Guoqiao Wang • 9 Nov 2023
Plasma p-tau217: a cost-effective and practical surrogate biomarker for clinical trials 3:32
Plasma p-tau217: a cost-effective and practical surrogate biomarker for clinical trials
Pamela Lukasewicz Ferreira • 30 Oct 2023
Objective monitoring of activities of daily living: IADLSys Smart-Home approach 3:19
Objective monitoring of activities of daily living: IADLSys Smart-Home approach
Ram Kinker Mishra • 8 Nov 2023
Amyloid reduction as a surrogate endpoint in Alzheimer’s disease trials: insights from DIAN-TU 2:13
Amyloid reduction as a surrogate endpoint in Alzheimer’s disease trials: insights from DIAN-TU
Guoqiao Wang • 9 Nov 2023
Unraveling the oligomer hypothesis in Alzheimer’s disease 4:02
Unraveling the oligomer hypothesis in Alzheimer’s disease
Eric Siemers • 8 Nov 2023
SEMA4D as a therapeutic target: insights from SIGNAL-HD and implications for Alzheimer’s disease 7:41
SEMA4D as a therapeutic target: insights from SIGNAL-HD and implications for Alzheimer’s disease
Terrence Fisher • 8 Nov 2023
SIGNAL-AD study of pepinemab in Alzheimer’s disease 2:03
SIGNAL-AD study of pepinemab in Alzheimer’s disease
Terrence Fisher • 8 Nov 2023
ACU193 in Alzheimer’s disease: insights from the INTERCEPT AD study 7:25
ACU193 in Alzheimer’s disease: insights from the INTERCEPT AD study
Eric Siemers • 8 Nov 2023
The content of VJDementia is intended for healthcare professionals